RegeneRx Biopharmaceuticals, Inc. announced today it was expanding its license to ReGenTree, LLC RGN-259 — a novel therapeutic peptide being developed for ophthalmic indications — in North America from just the U.S. to the U.S. and Canada.
RGN-259 is reportedly RegeneRx's Tβ4-based ophthalmic drug candidate that has been designated an orphan drug in the U.S. for the treatment of neurotrophic keratopathy (NK). In September 2015, RegeneRx — through its U.S joint venture, ReGenTree LLC — initiated a Phase 2/3 clinical trial in patients with dry eye syndrome and a Phase 3 clinical trial in patients with NK. The dry eye trial has been completed and the NK trial is estimated to be completed later in 2016 or 2017.
ReGenTree has also stated it expects report data from the recently completed dry eye trial to be released the week of May 2, 2016.
Click here to read the full press release.
Source: RegeneRx Biopharmaceuticals, Inc.